C1QBP and neoplasm: Above results confirmed the anti-tumor efficacy of gC1qR monoclonal antibody in cancer immunotherapy, but it is worth noting that in some specific tumors such as the glioblastoma, the blood–brain barrier may decrease the antitumor activity.